Adjusted for cell proportions: TRUE PR **PNR** PR - PNR ADA ADA ADA enriched in B cells (I) (LI.M47.0) enriched in B cells (II) (LI.M47.1) plasma cells & B cells, immunoglobulins (LI.M156.0) enriched in B cells (VI) (LI.M69) plasma cells, immunoglobulins (LI.M156.1) -B cell surface signature (LI.S2) enriched in B cells (III) (LI.M47.2) -TBA (LI.M114.0) cell cycle and transcription (LI.M4.0) enriched in T cells (I) (LI.M7.0) -T cell activation (I) (LI.M7.1) -Direction of effect extracellular matrix (II) (LI.M2.1) -Down at week 14 TBA (LI.M105) -Not significant TBA (LI.M55) -Gene module Up at week 14 blood coagulation (LI.M11.1) -Effect size (AUC) enriched in monocytes (IV) (LI.M118.0) -0.6 Monocyte surface signature (LI.S4) -0.7 myeloid, dendritic cell activation via NFkB (II) (LI.M43.1) -8.0 type I interferon response (LI.M127) -0.9 viral sensing & immunity; IRF2 targets network (II) (LI.M111.1) antiviral IFN signature (LI.M75) enriched in activated dendritic cells (II) (LI.M165) platelet activation - actin binding (LI.M196) platelet activation & blood coagulation (LI.M199) cell adhesion (LI.M51) enriched in myeloid cells and monocytes (LI.M81) enriched in neutrophils (I) (LI.M37.1) -TLR and inflammatory signaling (LI.M16) enriched in monocytes (II) (LI.M11.0) immune activation - generic cluster (LI.M37.0) -30 40

-log10(FDR)